Authors

Lacey J. Padrón, PhD

Latest:

Dr. Padrón on Biosignatures Found from a Phase 2 Study in Pancreatic Cancer

Lacey J. Padrón, PhD, discusses biosignatures found in a phase 2 study in pancreatic cancer.

Matthew J. Ehrhardt, MD, MS

Latest:

Dr. Ehrhardt on Factors Associated with Late Mortality in Survivors of Childhood Cancer

Matthew J. Ehrhardt, MD, MS, discusses the link between modifiable chronic health conditions and social determinants of health with late mortality for survivors of childhood cancer.

Eduardo Santos, MD, FACP, FCCP

Latest:

Dr Santos Castillero on Unmet Needs to Be Addressed in NSCLC

Edgardo S. Santos Castillero, MD, FACP, discusses current unmet needs that remain to be addressed in patients with relapsed/refractory non–small cell lung cancer.

Sarah Lang, MD, MBA

Latest:

Dr. Lee on the Association of MSI-H, dMMR, and TMB-H Features in Endometrial Cancer

Sarah Lee, MD, MBA, discusses the association of microsatellite instability–high, mismatch repair deficiency, and tumor mutational burden–high features in endometrial cancer.

Joseph Mikhael, MD

Latest:

Dr Mikhael on Unmet Needs to Be Addressed in Multiple Myeloma

Joseph Mikhael, MD, discusses unmet needs that remain to be addressed in the treatment of patients with multiple myeloma.

Mike Lattanzi, MD

Latest:

Dr Lattanzi on Findings From the PROpel trial in mCRPC

Mike Lattanzi, MD, discusses key findings from and implications of the PROpel trial in patients with metastatic castration-resistant prostate cancer.

Sara Corvigno, MD, PhD

Latest:

Dr Corvigno on Chemotherapy-Related Clonal Hematopoiesis in Ovarian Cancer

Sara Corvigno, MD, PhD, discusses the incidence of chemotherapy-related clonal hematopoiesis of indeterminate potential in patients with ovarian cancer.

Michael Wagner, MD

Latest:

Dr Wagner or the Potential Value of Immunotherapy in Angiosarcoma

Michael J. Wagner, MD, explains how immunotherapy may be a promising treatment approach for patients with angiosarcoma.

Carmelo Carlo-Stella, MD, PhD

Latest:

Dr Carlo-Stella on the FDA Approval of Glofitamab in Relapsed/Refractory DLBCL

Carmelo Carlo-Stella, MD, PhD, discusses the FDA approval of glofitamab for the treatment of patients with relapsed/refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after at least 2 lines of systemic therapy.

William Gradishar, MD, Northwestern Medicine

Latest:

Dr. Gradishar on the Significance of Drug Development in HER2+ Breast Cancer

William Gradishar, MD, discusses the significance of drug development in HER2-positive breast cancer.

Robert M. Rifkin, MD, FACP

Latest:

Dr Rifkin on the Role of Belantamab Mafodotin in Relapsed/Refractory Multiple Myeloma

Robert M. Rifkin, MD, FACP, offers advice to colleagues about belantamab mafodotin as a treatment option for patients with relapsed/refractory multiple myeloma.

Tucker Coston, MD

Latest:

Dr. Coston on the Investigation of Bone Metastases in Neuroendocrine Neoplasms

Tucker Coston, MD, discusses the investigation of bone metastases in patients with well-differentiated neuroendocrine neoplasms using gallium-68 DOTATATE positron emission tomography scans.

Julie Collins, MD, MedStar Georgetown University Hospital

Latest:

Dr. Collins on the Rationale for CDK4/6 Inhibitors in ER+ Breast Cancer

Julie M. Collins, MD, MPH, discusses the rationale for CDK4/6 inhibitors in endocrine receptor-positive breast cancer.

Jerome Zacks, MD

Latest:

Advice for Community Physicians Treating Patients with Neuroendocrine Tumor-Associated Carcinoid Syndrome

Drs Das, Pommier, and Zacks share their advice for community physicians treating patients who have neuroendocrine tumors with carcinoid syndrome and carcinoid heart disease.

Robert W. Mutter, MD

Latest:

Dr Mutter on the Benefit of Omitting Radiation Therapy in Node-Negative HR+ Breast Cancer

Robert W. Mutter, MD, discusses the potential benefit of radiation omission in node-negative hormone receptor-positive breast cancer.

Marco Ruella, MD

Latest:

Dr Ruella on Improving Access to CAR T-Cell Therapy for Minority Populations in Multiple Myeloma

Marco Ruella, MD, discusses strategies to improve access to CAR T-cell therapy for the management of multiple myeloma in minority health populations.

Jordan Hansford, MD

Latest:

Dr Hansford on HRQOL Outcomes With Tovorafenib in Pediatric BRAF-Altered Low-Grade Glioma

Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.

Sarah Nagle, MD

Latest:

Dr. Nagle on Investigational Cellular Therapies in Multiple Myeloma

Sarah Nagle, MD, assistant professor of medicine, School of Medicine, Oregon Health & Science University, discusses investigational cellular therapies in multiple myeloma.

Marie Hu, MD

Latest:

Dr Hu on Choosing Between Bispecific Antibodies vs CAR T-Cell Therapy in DLBCL

Marie Hu, MD, discusses her decision-making process when considering bispecific antibodies vs CAR T-cell therapy in patients with DLBCL.

Andrew G. Robinson, MD, MSc, FRCPC

Latest:

Dr. Robinson on the Updated Results of the KEYNOTE-407 Trial in Squamous NSCLC

Andrew G. Robinson, MD, MSc, FRCPC, discusses the updated results of the phase 3 KEYNOTE-407 trial in squamous non–small cell lung cancer.